View Older Stories

Aug 20, 2025 08:01AM Tharimmune reports simulation results for opioid exposure drug TH104

Aug 20, 2025 08:00AM Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Tr

Aug 13, 2025 08:01AM Tharimmune secures global patents for TH-104 opioid countermeasure drug

Aug 13, 2025 08:01AM Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl

Aug 5, 2025 08:00AM Tharimmune appoints Nancy Davis to board of directors

Aug 5, 2025 08:00AM Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors

Aug 4, 2025 08:01AM Tharimmune raises $5.47 million, advances fentanyl countermeasure TH104

Aug 4, 2025 08:00AM Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery

Jun 17, 2025 08:13AM Tharimmune (THAR) Announces Key Leadership Appointments

Jun 17, 2025 08:01AM Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors

May 19, 2025 08:01AM Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potenc

May 6, 2025 08:03AM Tharimmune (THAR) Presents Positive Clinical Data Highlighting TH104 Metabolic Profile

May 6, 2025 08:01AM Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

May 1, 2025 08:01AM Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences

Apr 30, 2025 08:03AM Tharimmune (THAR) Appoints Clay Kahler and Gary Stetz to its Board

Apr 30, 2025 08:01AM Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors

Apr 28, 2025 08:04AM Tharimmune (THAR) Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

Apr 28, 2025 08:01AM Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

Apr 15, 2025 09:00AM Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

Apr 7, 2025 08:00AM Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

Mar 31, 2025 08:03AM Tharimmune (THAR) Announces Positive FDA Feedback on NDA Path for TH104

Mar 31, 2025 08:00AM Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

Mar 24, 2025 08:00AM Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

Mar 4, 2025 07:03AM Tharimmune (THAR) Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

Mar 4, 2025 07:00AM Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

Jan 27, 2025 08:30AM Tharimmune to Present at the Microcap Conference 2025

Dec 19, 2024 04:18PM Tharimmune (THAR) Files for 1.44M Share Offering by Selling Stockholders

Dec 16, 2024 08:04AM Tharimmune (THAR) Announces Phase 2 Study Plan for TH104

Dec 16, 2024 08:00AM Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

Dec 6, 2024 04:20PM Tharimmune (THAR) Announces 961K Share Offering at $2.10/sh

Dec 6, 2024 04:15PM Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

Dec 6, 2024 09:57AM Rodman & Renshaw Starts Tharimmune, Inc. (THAR) at Buy

Nov 27, 2024 07:00AM DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

Nov 27, 2024 07:00AM DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

Nov 18, 2024 08:00AM Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Nov 13, 2024 08:03AM Tharimmune (THAR) Granted EU Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Nov 13, 2024 08:00AM Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Nov 4, 2024 09:00AM Tharimmune Announces Upcoming Conference Presentations

Oct 30, 2024 08:16AM Tharimmune (THAR) Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program

Oct 30, 2024 08:00AM Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

Oct 28, 2024 09:12AM Tharimmune (THAR) Presents Favorable TH104 Phase 1 Data

Oct 28, 2024 09:00AM Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

Oct 25, 2024 08:00AM Tharimmune Announces Upcoming Conference Presentations

Sep 30, 2024 07:23AM Tharimmune (THAR) to Merge With Intract Pharma

Sep 30, 2024 07:00AM Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

Sep 16, 2024 07:04AM Tharimmune (THAR) Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

Sep 16, 2024 07:00AM Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

Jul 22, 2024 08:30AM Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

Jul 17, 2024 08:31AM Tharimmune (THAR) Appoints David H. Clarke as Key Strategic Advisor

Jul 17, 2024 08:30AM Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

View Older Stories